Katelyn T. Byrne, Jinyang Li, R. Vonderheide, B. Stanger
{"title":"肿瘤细胞的内在因子决定了免疫细胞的浸润和对免疫治疗的反应","authors":"Katelyn T. Byrne, Jinyang Li, R. Vonderheide, B. Stanger","doi":"10.1158/2326-6074.CRICIMTEATIAACR18-A054","DOIUrl":null,"url":null,"abstract":"The establishment of immune heterogeneity in the tumor microenvironment (TME) is poorly understood, despite recent data that the success of immunotherapies is dictated by the immune environment of the tumor site. Pancreatic ductal adenocarcinoma (PDA) is characteristically devoid of CD8 T-cells and resistant to therapeutic intervention. However, a small subset of patients (15%) have tumors highly infiltrated by CD8 T-cells, correlating with improved overall survival. To better elucidate the determinants of immune heterogeneity in the PDA TME, we generated clones from spontaneous tumors harvested from KrasG12D+/-;Trp53R172H+/-;Pdx-1 Cre (KPC) mice, a genetically engineered mouse model of PDA. Using a panel of 17 tumor clones, we found the clones segregated in to two groups with differential immune cell infiltration upon implantation in congenic C57BL/6 mice. 7/17 tumor clones were categorized as “T-cell high,” with an immune infiltrate comprising CD8 T-cells and CD103+ dendritic cells (DCs). In contrast, the remaining 10 tumor clones were categorized as “T-cell low” lines, with the TME dominated by myeloid cells and macrophages, especially granulocytic myeloid-derived suppressor cells. Hypothesizing that increased T-cell infiltrate would render PDA sensitive to therapy, we treated two T-cell high and two T-cell low tumor clones with combination immunotherapy. Mice bearing T-cell high clones responded to therapy (7/7 and 4/7 mice cured) and formed protective memory responses against secondary tumor challenge, while none of the mice bearing T-cell low tumors responded to treatment (0/7 and 0/7 mice cured). At baseline, T-cell high tumors had similar proportions of functional CD8 T-cells as in T-cell low tumors. However, the proportion of activated CD44hiPD-1+ CD8 T-cells was significantly increased in T-cell high tumors (62.2% vs. 35.1% in T-cell low clones, p Citation Format: Katelyn T. Byrne, Jinyang Li, Robert H. Vonderheide, Ben Stanger. Tumor cell intrinsic factors dictate immune cell infiltration and response to immunotherapy [abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A054.","PeriodicalId":22141,"journal":{"name":"Tackling the Tumor Microenvironment: Beyond T-cells","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Abstract A054: Tumor cell intrinsic factors dictate immune cell infiltration and response to immunotherapy\",\"authors\":\"Katelyn T. Byrne, Jinyang Li, R. Vonderheide, B. Stanger\",\"doi\":\"10.1158/2326-6074.CRICIMTEATIAACR18-A054\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The establishment of immune heterogeneity in the tumor microenvironment (TME) is poorly understood, despite recent data that the success of immunotherapies is dictated by the immune environment of the tumor site. Pancreatic ductal adenocarcinoma (PDA) is characteristically devoid of CD8 T-cells and resistant to therapeutic intervention. However, a small subset of patients (15%) have tumors highly infiltrated by CD8 T-cells, correlating with improved overall survival. To better elucidate the determinants of immune heterogeneity in the PDA TME, we generated clones from spontaneous tumors harvested from KrasG12D+/-;Trp53R172H+/-;Pdx-1 Cre (KPC) mice, a genetically engineered mouse model of PDA. Using a panel of 17 tumor clones, we found the clones segregated in to two groups with differential immune cell infiltration upon implantation in congenic C57BL/6 mice. 7/17 tumor clones were categorized as “T-cell high,” with an immune infiltrate comprising CD8 T-cells and CD103+ dendritic cells (DCs). In contrast, the remaining 10 tumor clones were categorized as “T-cell low” lines, with the TME dominated by myeloid cells and macrophages, especially granulocytic myeloid-derived suppressor cells. Hypothesizing that increased T-cell infiltrate would render PDA sensitive to therapy, we treated two T-cell high and two T-cell low tumor clones with combination immunotherapy. Mice bearing T-cell high clones responded to therapy (7/7 and 4/7 mice cured) and formed protective memory responses against secondary tumor challenge, while none of the mice bearing T-cell low tumors responded to treatment (0/7 and 0/7 mice cured). At baseline, T-cell high tumors had similar proportions of functional CD8 T-cells as in T-cell low tumors. However, the proportion of activated CD44hiPD-1+ CD8 T-cells was significantly increased in T-cell high tumors (62.2% vs. 35.1% in T-cell low clones, p Citation Format: Katelyn T. Byrne, Jinyang Li, Robert H. Vonderheide, Ben Stanger. Tumor cell intrinsic factors dictate immune cell infiltration and response to immunotherapy [abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A054.\",\"PeriodicalId\":22141,\"journal\":{\"name\":\"Tackling the Tumor Microenvironment: Beyond T-cells\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Tackling the Tumor Microenvironment: Beyond T-cells\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR18-A054\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tackling the Tumor Microenvironment: Beyond T-cells","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR18-A054","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
摘要
尽管最近的数据表明免疫疗法的成功取决于肿瘤部位的免疫环境,但人们对肿瘤微环境(TME)中免疫异质性的建立知之甚少。胰腺导管腺癌(PDA)的特点是缺乏CD8 t细胞,并且对治疗干预具有抗性。然而,一小部分患者(15%)的肿瘤被CD8 t细胞高度浸润,这与改善的总生存率相关。为了更好地阐明PDA TME中免疫异质性的决定因素,我们从KrasG12D+/-、Trp53R172H+/-、Pdx-1 Cre (KPC)小鼠(一种PDA基因工程小鼠模型)的自发肿瘤中获得克隆。使用17个肿瘤克隆,我们发现克隆在基因C57BL/6小鼠体内植入后分化为两组,免疫细胞浸润差异。7/17的肿瘤克隆被归类为“高t细胞”,免疫浸润包括CD8 t细胞和CD103+树突状细胞(dc)。相比之下,其余10个肿瘤克隆被归类为“低t细胞”系,TME以骨髓细胞和巨噬细胞为主,特别是粒细胞骨髓源性抑制细胞。假设增加的t细胞浸润会使PDA对治疗敏感,我们用联合免疫疗法治疗了两个t细胞高和两个t细胞低的肿瘤克隆。携带t细胞高克隆的小鼠对治疗有反应(7/7和4/7小鼠治愈),并形成针对继发性肿瘤攻击的保护性记忆反应,而携带t细胞低克隆的小鼠对治疗没有反应(0/7和0/7小鼠治愈)。在基线时,高t细胞肿瘤具有与低t细胞肿瘤相似的功能性CD8 t细胞比例。然而,激活CD44hiPD-1+ CD8 t细胞的比例在t细胞高克隆肿瘤中显著增加(62.2%比在t细胞低克隆中增加35.1%,p引文格式:Katelyn T. Byrne, Jinyang Li, Robert H. Vonderheide, Ben Stanger。肿瘤细胞的内在因素决定了免疫细胞的浸润和对免疫治疗的反应[摘要]。第四届CRI-CIMT-EATI-AACR国际癌症免疫治疗会议:将科学转化为生存;2018年9月30日至10月3日;纽约,纽约。费城(PA): AACR;癌症免疫学杂志2019;7(2增刊):摘要nr A054。
Abstract A054: Tumor cell intrinsic factors dictate immune cell infiltration and response to immunotherapy
The establishment of immune heterogeneity in the tumor microenvironment (TME) is poorly understood, despite recent data that the success of immunotherapies is dictated by the immune environment of the tumor site. Pancreatic ductal adenocarcinoma (PDA) is characteristically devoid of CD8 T-cells and resistant to therapeutic intervention. However, a small subset of patients (15%) have tumors highly infiltrated by CD8 T-cells, correlating with improved overall survival. To better elucidate the determinants of immune heterogeneity in the PDA TME, we generated clones from spontaneous tumors harvested from KrasG12D+/-;Trp53R172H+/-;Pdx-1 Cre (KPC) mice, a genetically engineered mouse model of PDA. Using a panel of 17 tumor clones, we found the clones segregated in to two groups with differential immune cell infiltration upon implantation in congenic C57BL/6 mice. 7/17 tumor clones were categorized as “T-cell high,” with an immune infiltrate comprising CD8 T-cells and CD103+ dendritic cells (DCs). In contrast, the remaining 10 tumor clones were categorized as “T-cell low” lines, with the TME dominated by myeloid cells and macrophages, especially granulocytic myeloid-derived suppressor cells. Hypothesizing that increased T-cell infiltrate would render PDA sensitive to therapy, we treated two T-cell high and two T-cell low tumor clones with combination immunotherapy. Mice bearing T-cell high clones responded to therapy (7/7 and 4/7 mice cured) and formed protective memory responses against secondary tumor challenge, while none of the mice bearing T-cell low tumors responded to treatment (0/7 and 0/7 mice cured). At baseline, T-cell high tumors had similar proportions of functional CD8 T-cells as in T-cell low tumors. However, the proportion of activated CD44hiPD-1+ CD8 T-cells was significantly increased in T-cell high tumors (62.2% vs. 35.1% in T-cell low clones, p Citation Format: Katelyn T. Byrne, Jinyang Li, Robert H. Vonderheide, Ben Stanger. Tumor cell intrinsic factors dictate immune cell infiltration and response to immunotherapy [abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A054.